Does Immune Checkpoint Inhibition Have A Dark Side?

Share this content:
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

Tumors frequently evade the immune system at least in part via elevated cell-surface expression of PD-L1, which serves as an “invisibility cloak” for the growing malignancy. Immune checkpoint inhibitors counteract a key mechanism of immune evasion, activating patients' T cells to recognize and attack tumors. PD-1 inhibitors in particular, including nivolumab and pembrolizumab, are becoming a commonplace approach for treating cancer — though they can lead to significant toxicity.1

Researchers in Germany and Switzerland reported recently in Nature that PD-1 also serves as an “emergency shut-off switch” when T cells themselves become malignant.2 Oncogene proteins trigger increased PD-1 expression in healthy T cells, which can short-circuit the early development of premalignant T cells.

In gene sequencing analyses of 150 patients with T cell non-Hodgkin lymphoma (T-NHL), an aggressive and difficult-to-treat malignancy, the researchers found that 30% harbored mutations that disrupt PD-1 expression.

They also confirmed that, in an engineered mouse model of in T-NHL, disrupting PD-1 expression triggered a profound proliferation of malignant T cells — raising serious questions about possible unintended consequences for patients undergoing PD-1 immune checkpoint inhibition therapy in the clinic.

But T cell populations are functionally and phenotypically heterogeneous, so the clinical implications are not entirely clear, cautioned the authors of a commentary accompanying the study.3

Another study demonstrated that PD-1 blockade activates only specific subsets of T cells, noted Aya Ludin, PhD, and Leonard Zon, MD, of the Harvard Stem Cell Institute in Cambridge, Massachusetts.

“This suggests that anti-PD-1 treatment might aggravate disease progression only if it induces proliferation of the specific T-cell subtype that yielded the cancer,” they wrote.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs